Literature DB >> 15177883

Expression and motogenic activity of TFF2 in human breast cancer cells.

Felicity E B May1, Jennifer I Semple, Sara J Prest, Bruce R Westley.   

Abstract

The expression of TFF2 in breast cancer cells and the effect of recombinant TFF2 on breast cancer cell migration were assessed. TFF2 expression was detected by PCR in estrogen receptor-negative and at lower levels in estrogen receptor-positive breast cancer cells. TFF2 expression was detected in nine out of 10 primary breast tumors but its expression was not related to that of the estrogen receptor. Focal expression was observed in normal and tumor cells by immunohistochemistry. TFF2 stimulated the migration of estrogen-responsive MCF-7 and non-responsive MDA-MB231 cells. We conclude that TFF2 is expressed in normal and malignant breast epithelial cells and that it stimulates the migration of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177883     DOI: 10.1016/j.peptides.2003.12.024

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  11 in total

1.  Increased immunoexpression of trefoil factors in salivary gland tumors.

Authors:  Ponlatham Chaiyarit; Poramaporn Klanrit; Pensri Photipakdee; Ajiravudh Subarnbhesaj; Andrew S Giraud
Journal:  Clin Oral Investig       Date:  2014-05       Impact factor: 3.573

2.  Trefoil factor 2 negatively regulates type 1 immunity against Toxoplasma gondii.

Authors:  Cortez McBerry; Charlotte E Egan; Reena Rani; Yanfen Yang; David Wu; Nicholas Boespflug; Louis Boon; Barbara Butcher; Julie Mirpuri; Simon P Hogan; Eric Y Denkers; Julio Aliberti; De'broski R Herbert
Journal:  J Immunol       Date:  2012-08-15       Impact factor: 5.422

3.  Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines.

Authors:  Zinaida Dubeykovskaya; Alexander Dubeykovskiy; Joel Solal-Cohen; Timothy C Wang
Journal:  J Biol Chem       Date:  2008-12-08       Impact factor: 5.157

4.  The interaction of Helicobacter pylori with the adherent mucus gel layer secreted by polarized HT29-MTX-E12 cells.

Authors:  Brendan Dolan; Julie Naughton; Nicole Tegtmeyer; Felicity E B May; Marguerite Clyne
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

5.  A novel TFF2 splice variant (∆EX2TFF2) correlates with longer overall survival time in cholangiocarcinoma.

Authors:  Surasee Kamlua; Siriporn Patrakitkomjorn; Patcharee Jearanaikoon; Trevelyan R Menheniott; Andrew S Giraud; Temduang Limpaiboon
Journal:  Oncol Rep       Date:  2011-12-07       Impact factor: 3.906

6.  TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.

Authors:  Felicity E B May; Bruce R Westley
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

7.  Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.

Authors:  Yuko Ishibashi; Hiroshi Ohtsu; Masako Ikemura; Yasuko Kikuchi; Takayoshi Niwa; Kotoe Nishioka; Yoshihiro Uchida; Hirona Miura; Susumu Aikou; Toshiaki Gunji; Nobuyuki Matsuhashi; Yasukazu Ohmoto; Takeshi Sasaki; Yasuyuki Seto; Toshihisa Ogawa; Keiichiro Tada; Sachiyo Nomura
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

8.  Pancreatic-cancer-cell-derived trefoil factor 2 impairs maturation and migration of human monocyte-derived dendritic cells in vitro.

Authors:  Gi-Ho Sung; Hyun Chang; Ji-Yong Lee; Si Young Song; Han-Soo Kim
Journal:  Anim Cells Syst (Seoul)       Date:  2018-10-01       Impact factor: 1.815

9.  The trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1 preferentially in normal gastric mucosal cells but the co-expression of these proteins is deregulated in gastric cancer.

Authors:  Felicity E B May; S Michael Griffin; Bruce R Westley
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

10.  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).

Authors:  George Pentheroudakis; Vassiliki Kotoula; Elena Fountzilas; George Kouvatseas; George Basdanis; Ioannis Xanthakis; Thomas Makatsoris; Elpida Charalambous; Demetris Papamichael; Epaminontas Samantas; Pavlos Papakostas; Dimitrios Bafaloukos; Evangelia Razis; Christos Christodoulou; Ioannis Varthalitis; Nicholas Pavlidis; George Fountzilas
Journal:  BMC Cancer       Date:  2014-02-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.